Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease

Liu, Ru; Xiong, Fei; Wen, Yan; Ma, Yan; Yao, Yi; Gao, Zhan; Xu, Bo; Yang, Yuejin; Qiao, Shubin; Gao, Runlin; Yuan, Jinqing

doi:10.4103/0366-6999.209904

Cited by 6 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is because the inhibition of endothelization and the development of endothelial dysfunction. In addition, the future genetic mutations result in a decreased susceptibility to rapamycin and pharmacological resistance 55,56 . At the same time, the use of stable inorganic coatings helps to avoid the inflammatory response of endotheliocytes due to the barrier, which hampers the release of chemical elements from the substrate material 57,58 …”

Section: Resultsmentioning

confidence: 99%

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate

Grenadyorov

Solovyev

Оскомов

et al. 2022

J Biomedical Materials Res

View full text Add to dashboard Cite

The article deals with the plasma‐assisted chemical vapor deposition of 0.3–1.4 μm thick a‐C:H:SiOx films in a mixture of argon and polyphenylmethylsiloxane vapor onto the Ti–6Al–4V alloy substrate, which is often used as an implant material. The a‐C:H:SiOx film structure is studied by the Fourier‐transform infrared and Raman spectroscopies. The pull‐off adhesion test assesses the adhesive strength of a‐C:H:SiOx films, and the ball‐on‐disk method is employed to measure their wear rate and friction coefficient. According to these studies, a‐C:H:SiOx films are highly adhesive to the Ti–6Al–4V substrate, have low (0.056) friction coefficient and wear rate (9.8 × 10−8 mm3 N−1 m−1) in phosphate‐buffered saline at 40°C. In vitro studies show neither thrombogenicity nor cytotoxicity of the a‐C:H:SiOx film for the human blood mononuclear cells (hBMNCs). The in vitro contact between the hBMNC culture and a‐C:H:SiOx films 0.8–1.4 μm thick deposited onto Ti–6Al–4V substrates reduces a 24‐hour secretion of pro‐inflammatory cytokines and chemokines IL‐8, IL‐17, TNFα, RANTES, and MCP‐1. This reduction is more significant when the film thickness is 1.4 μm and implies its potential anti‐inflammatory effect and possible application in cardiovascular surgery. The dependence is suggested for the concentration of anti‐inflammatory cytokines and chemokines and the a‐C:H:SiOx film thickness, which correlates with the surface wettability and electrostatic potential. The article discusses the possible applications of the anti‐inflammatory effect and low thrombogenicity of a‐C:H:SiOx films in cardiovascular surgery.

show abstract

Section: Resultsmentioning

confidence: 99%

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate

Grenadyorov

Solovyev

Оскомов

et al. 2022

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…Our previous study also found that G1-DES had similar efficacy and safety profiles to G2-DES in patients with stable coronary artery disease. [ 11 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 8 9 10 ] Based on our previous report, G1-DES had similar efficacy and safety profiles to those of G2-DES in patients with stable coronary artery disease. [ 11 ] This impelled us to consider whether G2-DESs outperform G1-DESs in patients with acute coronary syndrome (ACS), a disorder with higher risks of adverse events after PCI. [ 12 ] Therefore, we aimed to identify the efficacy and safety of G1-DES and G2-DES in patients with ACS in a high-volume PCI center.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome

Tang

Yao

et al. 2018

Chinese Medical Journal

Self Cite

View full text Add to dashboard Cite

Background:It remains undetermined whether second-generation drug-eluting stents (G2-DESs) outperform first-generation DESs (G1-DESs) in patients with acute coronary syndrome (ACS). We aimed to compare the efficacy and safety of G1-DES and G2-DES in ACS patients in a high-volume cardiovascular center.Methods:In 2013, 10,724 consecutive patients underwent percutaneous coronary intervention in our institution. We included 4037 patients with ACS who underwent exclusively G1-DES or G2-DES implantation (n = 364 and n = 3673, respectively). We used propensity score matching to minimize the imbalance between the G1-DES and G2-DES groups and followed patients for 2 years. The efficacy endpoints were major adverse cardiac events (MACEs) and its components including target vessel-related myocardial infarction (TV-MI), target vessel revascularization/target lesion revascularization (TVR/TLR), and cardiac death. The safety endpoint was stent thrombosis. Continuous variables were compared by Mann-Whitney U-test, and categorical variables were compared using Pearson's Chi-square or Fisher's exact test. Kaplan-Meier curves were constructed to compare the event-free survival rates, and multivariate Cox proportional hazards regression analysis was used to assess whether stent type was an independent risk factor for the efficacy and safety endpoints.Results:At the 2-year follow-up, the results for MACE and it components, as well as stent thrombosis, were similar for G1-DES and G2-DES (MACE, 5.2% vs. 4.3%, χ2 = 0.514, P = 0.474; TV-MI, 0.8% vs. 0.4%, P = 0.407; TVR, 4.9% vs. 3.7%, χ2 = 0.939, P = 0.333; TLR, 3.8% vs. 2.5%, χ2 = 1.610, P = 0.205; cardiac death, 0.3% vs. 0.5%, P = 0.670; and stent thrombosis, 0.5% vs. 0.4%, P > 0.999). Kaplan-Meier analysis indicated similar event-free survival rates between G1-DES and G2-DES after propensity score matching (all: log-rank P > 0.05). Multivariate analysis demonstrated that stent type was not an independent risk factor for the efficacy and safety endpoints (MACE, hazard ratio [HR] = 0.805, 95% confidence interval [CI]: 0.455–1.424, P = 0.456; TV-MI, HR = 0.500, 95% CI: 0.101–2.475, P = 0.395; TVR, HR = 0.732, 95% CI: 0.403–1.330, P = 0.306; TLR, HR = 0.629, 95% CI: 0.313–1.264, P = 0.193; cardiac death, HR = 1.991, 95% CI: 0.223–17.814, P = 0.538; and stent thrombosis, HR = 0.746, 95% CI: 0.125–4.467, P = 0.749).Conclusion:G1-DES and G2-DES have similar efficacy and safety profiles in ACS patients at the 2-year follow-up.

show abstract

“…[ 2 ] Nevertheless, with increased risk of late stent thrombosis (ST) due to incomplete endothelialization and inflammatory response, first-generation DES is restricted to longer-term dual antiplatelet therapy compared with bare-metal stent (BMS). [ 3 ] Recent network meta-analysis indicates that new-generation DES is associated with significantly lower rates of ST as compared to BMS and first-generation DES, which makes it an appropriate choice for the treatment of ISR. [ 4 ]…”

Section: Introductionmentioning

confidence: 99%

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis

Cui

Lyu

Zhang

et al. 2018

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Currently, drug-eluting balloon (DEB) appears to be an attractive alternative option for the treatment of in-stent restenosis (ISR). Nevertheless, the clinical outcomes of DEB have seldom been compared to those of new-generation drug-eluting stent (DES). Thus, this meta-analysis aimed to evaluate the safety and efficacy of DEB compared to those of new-generation DES in the treatment of ISR.Methods:A comprehensive search of electronic databases including PubMed, EMBASE, and Cochrane Library up to November 2, 2017 was performed to identify pertinent articles comparing DEB to new-generation DES for the treatment of ISR. In addition, conference proceedings for the scientific sessions of the American College of Cardiology, American Heart Association, European Society of Cardiology, Transcatheter Cardiovascular Therapeutics, and EuroPCR were also searched. The primary endpoint was target lesion revascularization (TLR) at the longest follow-up. Dichotomous variables were presented as risk ratios (RR s) with 95% confidence intervals (CIs), while the overall RRs were estimated using the Mantel-Haenszel random-effects model.Results:Five randomized controlled trials (RCTs) and eight observational studies involving 2743 patients were included in the present meta-analysis. Overall, DEB was comparable to new-generation DES in terms of TLR (RR = 1.24, 95% CI: 0.89–1.72, P = 0.21), cardiac death (RR = 1.55, 95% CI: 0.89–2.71, P = 0.12), major adverse cardiovascular event (RR = 1.21, 95% CI: 0.98–1.48, P = 0.07), myocardial infarction (RR = 1.12, 95% CI: 0.72–1.76, P = 0.62), and stent thrombosis (RR = 0.95, 95% CI: 0.38–2.42, P = 0.92). However, DEB was associated with higher risk of all-cause mortality than new-generation DES (RR = 1.65, 95% CI: 1.09–2.50, P = 0.02). This was especially true in the real-world observational studies (RR = 1.79, 95% CI: 1.12–2.88, P = 0.02). In RCTs, however, no significant difference was found between the two treatment strategies in the risk of all-cause mortality.Conclusions:The current meta-analysis showed that DEB and new-generation DES had comparable safety and efficacy for the treatment of ISR in RCTs. However, treatment with DEB was associated with higher risk of all-cause mortality in the real-world nonrandomized studies.

show abstract

Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease

Cited by 6 publications

References 24 publications

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate

Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis

Contact Info

Product

Resources

About

Comparison of Efficacy and Safety between First and Second Generation Drug-eluting Stents in Patients with Stable Coronary Artery Disease

Cited by 6 publications

References 24 publications

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiOx‐coated Ti–6Al–4V substrate

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiOx‐coated Ti–6Al–4V substrate

Comparison of Efficacy and Safety between First- and Second-Generation Drug-Eluting Stents in Patients with Acute Coronary Syndrome

Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis

Contact Info

Product

Resources

About

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate

Morphofunctional reaction of leukocytes and platelets in in vitro contact with a‐C:H:SiO_x‐coated Ti–6Al–4V substrate